中國醫療(08225.HK)彈14%曾高見1.08元 春立/阿里健康/威高/愛康由紀錄高續吐近2%-6%
中國醫療集團(08225.HK)抗新冠肺炎藥邁可欣即將開展海外臨床研究,該股今天曾一舉重越10天、20天及50天線(0.89元/0.94元/1.04元),一度急彈30%高見1.08元遇壓,現造0.94元,急彈14%,一向薄弱成交急增至3,372萬股,涉資3,325萬元。中國醫療公布,為回應國際抗擊新冠肺炎疫情緊急需求,與一家國際CRO公司Pharmadesk簽署《邁可欣口服液生物等效性研究協議》。該產品為集團關聯製造企業「萬全萬特製藥(廈門)」於今年2月下旬獲得獨家複產批准的產品(已被中國科學院等研究機構發現對新冠肺炎有抑制作用)。
相反,其餘醫藥相關股普遍受壓,且沽壓遠超大市。藍籌石藥(01093.HK)低見15.08元,現造15.28元,回吐4.1%。藥明生物(02269.HK)高開報122.7元欠承接,受制上月盤中所創上市高位123.8元,掉頭失守10天線(117.1元),最低見116元,現造116.6元,倒跌4%,旗下藥明康德(02359.HK)低見104元,現造105.6元,續吐3.2%。
正探討發A股可能性的春立醫療(01858.HK)股價由紀錄高位連吐第二天,今天反覆續吐5.7%報44.15元即市低位;阿里健康(00241.HK)扭轉連續兩天破頂強勢,股價回吐5.4%,報18.54元。威高股份(01066.HK)及愛康醫療(01789.HK)由紀錄高位連吐第二天,現造12.22元及22.65元(均為即市低位),反覆續吐1.9%及2.4%。
復星醫藥(02196.HK)扭兩連漲,股價由52周高位反覆回吐逾1%曾低見29.1元;上海醫藥(02607.HK)扭四連漲,股價跌2%報13.84元,失守10天線(13.93元)。聯邦制藥(03933.HK)扭兩連漲,股價回吐3.6%報6.96元,失守10天線(7.15元)。不過,昨天高位遇壓倒跌的康希諾生物-B(06185.HK)曾回升至149.1元,現造146元,回升2.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.